KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Abbott Laboratories (ABT) Operating Income (2016 - 2025)

Abbott Laboratories' Operating Income history spans 17 years, with the latest figure at $2.3 billion for Q4 2025.

  • For Q4 2025, Operating Income rose 17.79% year-over-year to $2.3 billion; the TTM value through Dec 2025 reached $8.1 billion, up 17.99%, while the annual FY2025 figure was $8.1 billion, 17.99% up from the prior year.
  • Operating Income for Q4 2025 was $2.3 billion at Abbott Laboratories, up from $2.1 billion in the prior quarter.
  • Across five years, Operating Income topped out at $2.9 billion in Q1 2022 and bottomed at $1.3 billion in Q4 2022.
  • The 5-year median for Operating Income is $1.8 billion (2023), against an average of $1.9 billion.
  • The largest annual shift saw Operating Income surged 178.23% in 2021 before it crashed 48.18% in 2023.
  • A 5-year view of Operating Income shows it stood at $2.4 billion in 2021, then plummeted by 45.16% to $1.3 billion in 2022, then surged by 36.5% to $1.8 billion in 2023, then increased by 7.36% to $1.9 billion in 2024, then grew by 17.79% to $2.3 billion in 2025.
  • Per Business Quant, the three most recent readings for ABT's Operating Income are $2.3 billion (Q4 2025), $2.1 billion (Q3 2025), and $2.1 billion (Q2 2025).